A Message from the Chair
A modern medical miracle
I consider stem cells to be a modern medical miracle – the most exciting advance in medicine since antibiotics. Yet just a few years ago, Michigan’s scientists couldn’t make new stem cell lines. Well, they could – but they would be committing a crime that could land them in jail for 10 years and cost them $10 million.
Thankfully, Michigan voters spoke out loudly in favor of curing diseases when in 2008 they approved a constitutional amendment lifting restrictions on stem cell research.
Since then, the progress we have made throughout the state in stem cell research has been nothing short of remarkable. Our great research institutions are hiring new scientists and doing cutting-edge work. The biotech industry is heating up, creating jobs and new opportunities. We’re on the verge of new, life-saving advances in medicine as a result of this burgeoning frontier of research.
At the University of Michigan, the scientists of the Taubman Institute are making incredible progress. Dr. Eva Feldman, our director, is conducting the first human clinical trial of a stem cell treatment for ALS, that terrible condition known as Lou Gehrig's disease. Dr. Max Wicha, a Taubman Scholar and director of the Comprehensive Cancer Center, is leading the first-ever clinical trial targeting cancer stem cells. The Taubman Institute also has established the Consortium for Stem Cell Therapies, one of the few facilities in the nation to produce new embryonic stem cell lines that contain the genetic defects for specific diseases.
I founded the Taubman Institute to support innovative medical science like stem cell research. We are supporting the work of 12 Taubman Scholars, senior physician-scientists working in crucial fields of research such as cancer, cardiovascular disease and neurological disorders. We have also launched an Emerging Scholars Program to foster the careers of promising young physician-scientists.
Yes, it is an exciting time to be in Michigan if you are a medical scientist. We are making crucial laboratory discoveries. More importantly, we’re moving that progress from bench to bedside, where it can help patients suffering from disease. That is the true goal of the Taubman Institute.
A. Alfred Taubman
Founder and Chair, A. Alfred Taubman Medical Research Institute
Stem cell symposium set for Sept. 19 in Ann Arbor
Dr. Eva Feldman will be among the speakers at the one-day event, which focuses on cutting-edge developments in stem-cell biology, epigenetics and regneratrive medicine.
Click here for details and registration.
New Emerging Scholar named
Scott Tomlins, M.D., an assistant profesor of pathology at U-M, has been designated the A. Alfred Taubman Emerging Scholar. Dr. Tomlins is an expert in prostate cancer research.
People who care
Institute welcomes new gift officer
Maria Muller has been appointed to work with connect donors with funding opportunities at the Taubman Institute.
Click here to read more.
news & events
Institute symposium set for Oct. 10
The A. Alfred Taubman Medical Research Institute will award the 2014 $100,000 Taubman Prize for Excellence in Translational Medical Science at its 7th annual symposium at 10 a.m. on Oct. 10.
Dr. Carl June, a physician-scientist who developed a personalized immunotherapy for leukemia using patients’ own T cells, will receive the honor and deliver the symposium's keynote address.
Click here for symposium details.
Drug cuts risk of bone-marrow transplant side effect
Taubman Emerging Scholar Sung Won Choi, M.D., is the lead author of a new study that finds a new way to help prevent graft-vs-host disease in cancer patients receiving bone-marrow transplants.
Study: Two types of cancer stem cells lead to metastasis
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to a new study published by Taubman Senior Scholar Dr. Max Wicha.